X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs CIPLA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES CIPLA PIRAMAL ENTERPRISES/
CIPLA
 
P/E (TTM) x 36.5 44.8 81.5% View Chart
P/BV x 3.0 3.8 79.0% View Chart
Dividend Yield % 0.8 0.3 239.9%  

Financials

 PIRAMAL ENTERPRISES   CIPLA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
CIPLA
Mar-17
PIRAMAL ENTERPRISES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,095622 336.9%   
Low Rs1,025458 223.7%   
Sales per share (Unadj.) Rs492.8181.9 271.0%  
Earnings per share (Unadj.) Rs72.612.9 563.8%  
Cash flow per share (Unadj.) Rs94.729.3 323.0%  
Dividends per share (Unadj.) Rs21.002.00 1,050.0%  
Dividend yield (eoy) %1.30.4 363.5%  
Book value per share (Unadj.) Rs862.5155.7 554.0%  
Shares outstanding (eoy) m172.56804.51 21.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.23.0 106.6%   
Avg P/E ratio x21.542.0 51.2%  
P/CF ratio (eoy) x16.518.4 89.4%  
Price / Book Value ratio x1.83.5 52.1%  
Dividend payout %28.915.5 186.3%   
Avg Mkt Cap Rs m269,194434,516 62.0%   
No. of employees `0004.023.0 17.4%   
Total wages/salary Rs m17,93926,338 68.1%   
Avg. sales/employee Rs Th21,190.36,349.1 333.8%   
Avg. wages/employee Rs Th4,470.11,143.0 391.1%   
Avg. net profit/employee Rs Th3,120.0449.3 694.3%   
INCOME DATA
Net Sales Rs m85,037146,302 58.1%  
Other income Rs m2,3382,287 102.2%   
Total revenues Rs m87,374148,589 58.8%   
Gross profit Rs m34,99124,758 141.3%  
Depreciation Rs m3,81713,229 28.9%   
Interest Rs m20,3101,594 1,274.3%   
Profit before tax Rs m13,20212,222 108.0%   
Minority Interest Rs m1,6990-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,2811,798 126.9%   
Profit after tax Rs m12,52010,354 120.9%  
Gross profit margin %41.116.9 243.2%  
Effective tax rate %17.314.7 117.5%   
Net profit margin %14.77.1 208.0%  
BALANCE SHEET DATA
Current assets Rs m87,59087,370 100.3%   
Current liabilities Rs m185,57833,081 561.0%   
Net working cap to sales %-115.237.1 -310.5%  
Current ratio x0.52.6 17.9%  
Inventory Days Days3187 35.7%  
Debtors Days Days4862 76.3%  
Net fixed assets Rs m108,523111,567 97.3%   
Share capital Rs m3451,609 21.4%   
"Free" reserves Rs m148,481123,645 120.1%   
Net worth Rs m148,826125,254 118.8%   
Long term debt Rs m144,95736,454 397.6%   
Total assets Rs m482,394209,532 230.2%  
Interest coverage x1.78.7 19.0%   
Debt to equity ratio x1.00.3 334.7%  
Sales to assets ratio x0.20.7 25.2%   
Return on assets %6.85.7 119.4%  
Return on equity %8.48.3 101.8%  
Return on capital %12.08.5 140.6%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m15,00151,066 29.4%   
Fx outflow Rs m5,15017,678 29.1%   
Net fx Rs m9,85133,388 29.5%   
CASH FLOW
From Operations Rs m-100,39323,824 -421.4%  
From Investments Rs m-24,202-13,127 184.4%  
From Financial Activity Rs m135,705-13,239 -1,025.1%  
Net Cashflow Rs m11,110-2,478 -448.3%  

Share Holding

Indian Promoters % 52.9 16.0 330.6%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 4.0 12.2 32.8%  
FIIs % 26.6 23.7 112.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 16.5 26.2 63.0%  
Shareholders   93,274 161,166 57.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   SHASUN PHARMA  WYETH LTD  ASTRAZENECA PHARMA  SUVEN LIFE  STERLING BIOTECH  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; IT Stocks Gain(09:30 am)

Asian stocks were relatively subdued in the early trade today, with most regional indices hovering around the flat line following the softer lead stateside.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Feb 21, 2018 10:43 AM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS